Drug lookup | Fillwise

BROMOCRIPTINE

All products: not a benefit

Other products in the same Health Canada class (G02CB) — coverage varies; not interchangeable

Cabergoline (Dostinex): limited Use 656
Quinagolide (Norprolac): limited Use 405

Parlodel · DIN 00371033 · 2.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.Discontinued 2007-07-18 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Parlodel · DIN 00371033 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-07-18 · brand PARLODEL TAB 2.5MG · ATC G02CB01 BROMOCRIPTINE · form Tablet · route Oral · ingredients BROMOCRIPTINE (BROMOCRIPTINE MESYLATE) 2.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Parlodel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2539 · Verify on the e-Formulary ↗ (DIN 00371033)

Source record

DIN 00371033: Parlodel Raw flags: notABenefit=Y, sec3=Y Item: 920000029; group id 900; item number 2159; lccId None; manufacturer id NOV Source form: Tab; strength: 2.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00371033 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2539

Interchangeable products

Bromocriptine · DIN 02087324 · $1.0800

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00371033

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2007-07-18 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

CABERGOLINE

· 3 products · Limited Use, codes 656 · strengths: 0.5mg · Tab

QUINAGOLIDE HCL

· 1 products · Limited Use, codes 405 · strengths: 0.15mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more

Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: acromegaly, parkinsons disease

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LANREOTIDE ACETATE LANREOTIDE ACETATE · General benefit 1 INDICATIONS SOMATULINE® AUTOGEL® [lanreotide (as lanreotide acetate) injection] is indicated for: • The long-term treatment of adult patients with acromegaly due to pituitary tumours who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. PM: https://pdf.hres.ca/dpd_pm/00071957.PDF; date JUL 17, 2006; DIN 02283395; fetched 2026-09-10 Product monograph LEVODOPA & CARBIDOPA · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) 1 INDICATIONS APO-LEVOCARB (levodopa and carbidopa tablets) is indicated for the treatment of Parkinson's disease. PM: https://pdf.hres.ca/dpd_pm/00076848.PDF; date AUG 27, 2024; DIN 02195933; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS BROMOCRIPTINE (Bromocriptine Mesylate) is indicated for:  Galactorrhea with or without amenorrhea due to hyperprolactinemia.  Prolactin-dependent menstrual disorders and infertility: e.g. secondary amenorrhea, ovulatory insufficiency and short luteal phase.  Prolactin-secreting adenomas: as a treatment for inoperable macroadenomas or prior to surgery in order to facilitate removal, and as an alternative to surgery in patients with microadenomas.  Prolactin-dependent male hypogonadism.  Acromegaly: the first-line treatment of this condition is by surgery or radiotherapy. BROMOCRIPTINE (bromocriptine mesylate) may be a useful adjunct to such treatment, and can be used as monotherapy in special cases.  Parkinson’s Disease: BROMOCRIPTINE is effective when used as adjunct therapy to levodopa in the symptomatic management of Parkinson’s Disease. Used concomitantly with levodopa, bromocriptine facilitates the use of lower doses of levodopa in early disease and attenuates the rate of increase in the levodopa dosages on long-term usage. In this way the risk of long– term complications su… https://pdf.hres.ca/dpd_pm/00064762.PDF PM date: FEB 16, 2022 Source product: BROMOCRIPTINE; DIN 02087324; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Parlodel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026